Orbit Genomics Investor Update & Deep Dive

Orbit Genomics® is redefining precision medicine with OrbiSeq™, the first AI-powered platform that accurately analyzes short tandem repeats—dynamic, stress-responsive DNA sequences that reveal both inherited disease risk and risk acquired from living. Unlike traditional tests focused on static genetic mutations (SNPs), OrbiSeq delivers a personalized, actionable view of health and disease trajectory.

This session provides an opportunity for RVC portfolio company, Orbit Genomics, to update existing RVC Investors while engaging those interested in the current follow-on investment.

The RVC Deep Dive is a 90 minute virtual meeting held between company executive leadership, RVC Investors, and RVC staff. The purpose of this meeting is to cover all major due diligence questions such as business strategy, team, product, competition, IP, market, traction, key risks, and exit strategy. 

The structure of the meeting is as follows:

• Company Pitch (15 minutes)
• Guided Q&A w/ Investors (45 minutes)
• Investor Only Discussion (30 minutes)

To attend, you must be an accredited investor (net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 together with his or her spouse if married] and have the expectation to make the same amount this year). We do not require a minimum investment.